Healthcare / Drug Manufacturers - Specialty & GenericBSE
$0.37
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-741.6M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$326M
P/E
2.8x
↓EV/EBITDA
5.5x
↓ROE
4.9%
↑Gross Margin
1.8%
↓Debt/Equity
1.02
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.1%
FCF CAGR
—
FCF margin
-282.4%
FCF / Net income
-537.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.05B · net income $21.3M · FCF $-11.44B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.05B | $4.05B | $40.42B | $5.10B | $5.05B |
| Net Income | $21.3M | $21.3M | $327.3M | $54.3M | $10.8M |
| EBITDA | $120.4M | $120.4M | $545.3M | $76.2M | $17.8M |
| EPS | 0.03 | 0.03 | 0.57 | 0.09 | 0.02 |
| Gross Margin | 1.8% | 1.8% | 1.0% | 3.1% | 1.3% |
| Operating Margin | 0.3% | 0.3% | 0.8% | 1.7% | 0.3% |
| Net Margin | 0.5% | 0.5% | 0.8% | 1.1% | 0.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.02 | 1.02 | 1.34 | — | — |
| Current Ratio | 1.06 | 1.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.44B | $-11.44B | $-741.6M | $204.6M | $112.3M |
| Returns | |||||
| ROE | 4.9% | 4.9% | 76.2% | 52.4% | 21.8% |
| Valuation | |||||
| P/E | 2.85 | 2.85 | 211.51 | 1623.38 | 1322.95 |
| EV/EBITDA | 5.48 | 5.48 | 128.11 | 1155.99 | 801.42 |
| P/B | 0.49 | 0.49 | 161.30 | 849.76 | 288.37 |
| Growth & Yield | |||||
| Revenue Growth | -90.0% | -90.0% | 692.7% | 1.0% | — |
| EPS Growth | -93.8% | -93.8% | 503.8% | 404.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-2.0%
EPS terminal req.
$0.03
Spread vs growth
-91.8%
5Y implied EPS CAGR
2.6%
EPS terminal req.
$0.04
Spread vs growth
-96.5%
10Y implied EPS CAGR
6.2%
EPS terminal req.
$0.06
Spread vs growth
-100.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-78.5%
Start / end P/E
3.1x → 10.9x
EPS bridge
0.57 → 0.03
Residual
-233.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.